NEOG arrives at its October 1 earnings release in a peculiar spot: short interest has surged 44% over the past month, options traders are loading up on calls, and the stock just dropped 9% in a week from a price level that still represents a near-doubling for 2026.
The short book is the most active it has been in this cycle. Short interest climbed 7% over the past week to 5.3% of the free float, with roughly 11.4 million shares now borrowed. Days to cover runs at 4.5. That monthly build of 44% is the fastest in the recent dataset and marks a meaningful shift in conviction from bears who had largely stood aside during the year's rally. What makes the positioning unusual is the complete absence of squeeze pressure: availability is above 1,190%, meaning there are more than eleven shares available to lend for every one already borrowed. The cost to borrow is 0.39%, near its floor for the year. Bears are adding, but cheaply and without crowding risk.
Options positioning runs in the opposite direction. The put/call ratio of 0.28 sits nearly 1.2 standard deviations below its 20-day average of 0.38, placing call demand at one of its more extreme readings of recent months. The 52-week range for the PCR runs from 0.15 to 1.38, so the current reading is toward the bullish end but not at an all-time skew. The divergence between a growing short book and a call-heavy options strip is the defining tension heading into the print: one camp is paying to go up, the other is betting the rally overshoots.
The Street has grown more constructive through the year, though not unanimously. Guggenheim raised its target to $14 from $12 this morning while maintaining its Buy. Piper Sandler upgraded to Overweight in late August, lifting its target to $14. Those moves bring the consensus price target to $14, a modest 10% above Tuesday's close of $12.73 after the stock shed 7.2% on September 29 alone. The bull case rests on Neogen's positioning in food and animal safety diagnostics, a market with secular tailwinds from tightening regulatory standards. Bears point to decelerating revenue growth and margin pressure from supply chain costs. The EPS forward momentum score ranks in the 90th percentile for year-on-year estimate increases, yet the EPS surprise factor sits at only the 5th percentile, meaning the company has a history of disappointing relative to what analysts embed at the time of the print.
That last point makes the earnings history worth noting. The most recent quarterly result, reported July 30, produced a one-day move of plus 28% and a five-day move of plus 20%. The prior period showed a much smaller one-day move of under 1% but a five-day drift of plus 26%. Neogen has a pattern of large post-earnings moves in both directions, but the recent instance was a sharp upward surprise. That history partly explains the call skew: traders familiar with the July move may be positioning for a repeat, even as the short book reflects scepticism that the current price level is justified.
Retail attention is also elevated. Wikipedia page views rank 2.8 standard deviations above Neogen's own 90-day norm, the highest attention reading in the alt data layer for this name. That is a measure of interest, not a revenue signal, but it is consistent with a stock that has moved dramatically and is now approaching a scheduled catalyst. On the institutional side, Neuberger Berman added more than 8.8 million shares in the period through August 31, making it the second-largest holder at 7.6% of shares. BlackRock remains the largest at 15.3%. No 13D activist is on the register; all large-holder filings are passive 13G disclosures, with stakes as last disclosed around the 5% threshold.
The October 1 print will test whether the July earnings surprise was a turning point or an outlier, and the split between a growing short base and an unusually call-heavy options strip means the market is genuinely uncertain which way the answer lands.
See the live data behind this article on ORTEX.
Open NEOG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
